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Supportive Care of the
Leukemic Patient
Ellis J. Van Slyck, M D *

Improvement in remission rate and length
of survival overall in acute leukemia can be
credited in large measure to better management of the hemorrhagic complications and
the infections seen in most of these patients.
Particularly is this so during the post-treatment phase of cyclic chemotherapy when
severe marrow aplasia and peripheral pancytopenia become intense. Today roughly
11 % of patients with acute leukemia die of
hemorrhage alone, 69% die of infection
alone, and the remainder die of both factors
or some other cause.' This essay will attempt a concise review of current measures
and approaches available in support of the
patient whose condition is marrow-depressed and i m m u n o l o g i c a l l y c o m p r o mised.

The outlook for the patient with leukemia
or lymphoma has been improved by the
exponential expansion of basic scientific
knowledge in physical chemistry and microbiology, added to much new clinical
information
based on large
cooperative
group studies. Most of this progress derives,
not from a specific treatment for the disease,
but from better understanding and use of
multiple support measures. These include
the availability of blood components, such
as red blood cell, platelet and granulocyte
concentrates, better protective
Isolation
measures, and greater expertise In the recognition and treatment of bacterial, fungal,
and viral Infections in immunosuppressed
patients. In addition, the management of
associated metabolic disturbances, such as
hyperkalemia, hyperuricemia, and hypercalcemia, is now based on firm ground. A
review of the major progress In these various areas of supportive care comprises this
essay.

1. Blood Cell Component
Therapy
The use of whole blood should be restricted to episodes of massive hemorrhage.
When there is need to support a falling
hemoglobin level due to unremitting blood
loss and/or marrow hypoplasia, packed red
blood cells should be the first choice. Advantages over whole blood are less total
volume, and less sodium intake. Sodium
balance may be critical in the many patients
who are receiving, concomitantly, corticosteroids (Na"*" retention) and carbenicillin
(high Na^ content). Furthermore, packed
cells contain less alloimmunizing material
in the suspending plasma, and, generally,
patients tolerate packed cells longer than
whole blood before developing pyrogenic
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or other reactions. In our experience, increasingly frequent pyrogenic episodes occurring with succeeding packed cell transfusions can often be controlled by removing
the buffy coat of the packed cells with a
pipette prior to administration. This observation suggests that leukocyte or platelet
antigens are responsible for most of these
febrile reactions.

including this author, feel it is better to wait
for episodes of frank and significant bleeding. In favor of the first position can be cited
a study in children by Roy,^ who observed a
26% incidence of major bleeding at platelet
counts below 10,000 per cu mm. This is a
significantly greater figure than that seen in
children receiving both low and high dose
platelet concentrates daily. Furthermore, it
cannot be denied that the first manifestation
of a severe hemorrhagic complication can
be a fatal cerebral or gastrointestinal hemorrhage, occurring too rapidly to be controlled by platelet transfusions " o n demand."
Ffowever, the rapid development of alloimmunization to random donor platelets, coupled with long periods of marrow suppression seen after many courses of chemotherapy, makes the " o n demand" use of
platelets superior, in my view. There are
other hazards in administering platelets besides alloimmunization; such as the transmission of hepatitis virus, cytomegalovirus,
or toxoplasmosis. Rarely, the transmission
of bacterial contaminants from platelets
stored at room temperature as well as graftvs-host reactions from lymphocytes present
in the concentrates have been described in
severely immunosuppressed recipients.

Frozen Stored Red Cells
Occasionally, when transfusion reactions
are resistant to the above maneuvers, one
can use frozen red cells, which are thawed,
washed, and resuspended in saline. It is
necessary to wash out the glycerol (a
cryoprotective agent). These preparations
are expensive, and the donor red cells are,
per force, somewhat damaged. Therefore,
survival in the recipient is shortened.
Frozen red cells may be the transfusion
method of choice despite the drawbacks, in
situations involving very rare blood types
and severe alloimmunization reactions to
plasma proteins, white cells or platelets.

Platelet Concentrates
When it is possible, there is a greater
advantage in using HL-A matched donors
for platelets, matched at least at the four
major loci." These donors are generally
siblings of the patient. Parents and children
of the patient will have two matched loci,
rarely more, but are better donors than
random donors. The chances of finding a
four antigen HL-A match from an unrelated
donor is one in 10,000 or 20,000. Non-HLA platelet specific antigens can produce
sensitization even in matched siblings. And,
there is the further problem of "locking i n "
a donor to a protracted, tedious regime,
once he or she is identified.

It is now practicable to prepare and administer platelet concentrates (generally in
numbers equivalent to 4-12 units of donor
blood, reduced to a volume of 50-150 cc).
The effective functional life of the donor
platelet is probably no more than 48 hours,
and, with succeeding boli of pooled random platelets, rapid alloimmunization develops in the recipient. Thus, after three to
eight platelet transfusions, the progressively
more rapid destruction of donor platelets in
the recipient makes their value nil. The best
practical guide to judging the effectiveness
of a given bolus of platelets is performing a
post-transfusion count and observing the
clinical effect on hemostasis.^ Some oncologists have recommended giving prophylactic donor platelets daily or every
other day, when the platelet count reaches
levels below 20,000 per cu mm. Others,

Platelets may be stored at 4°C or 22°C.
Those at the colder temperatures require
warming before administration. Platelets at
4°C do not survive as well in the recipient as
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platelets at room temperature, but they appear to respond to aggregating agents in
vitro better than those at room temperature.
In vivo studies also show correction of
bleeding times by 4°C platelets immediately
after infusion, but not by 22°C platelets,
although the latter seem to regain their
hemostatic properties after a few hours. We
are currently using 22°C platelets routinely.

Because thrombocytopenia may well be
d r u g - or l e u k e m i a - r e l a t e d , low platelet
counts may not be a helpful diagnostic sign,
but, when present, prolongation of the prothrombin time, partial thromboplastin time,
and decreased factor VIII and V assays are
indicative of the condition. The syndrome
occurs frequently as a result of coincident
septicemia during the course of leukemia.
In this situation, prompt and vigorous treatment of the infection (to be discussed later)
is more helpful than is heparin. If severe and
generalized bleeding is due to DIC, the
administration of heparin (starting with low
doses —10,000-15,000 u/d—and increasing cautiously, if necessary) is an accepted
maneuver. O b t a i n i n g serial serum
fibrinogen and fibrin split product assays is
the best way to monitor the response to
heparin, in addition to observing clinical
control of bleeding.

T h e o r e t i c a l l y , the use of autologous
platelets collected from the recipient at a
previous time in anticipation of later need,
is the best source. In a few investigative
studies, these autologous platelets have indeed demonstrated their effectiveness.^
However, long term preservation, using either 5% DSMO or 5% glycerol as cryopreservatives, has not been entirely satisfactory. Thawing of platelets and washing out
of the preservatives prior to administration
damage the platelets. Current investigative
work concerns finding optimum rates for
freezing, optimum freezing temperature,
best v o l u m e of concentrate, best c r y o preservative, and its best concentration, etc.
Precollected autologous platelets are not a
practical tool, at present.

Granulocyte Transfusions
Some institutions involved in the aggressive treatment of acute leukemia and the
lymphomas are coming to the use of granulocyte concentrates in the management of
the neutropenic and septic patient. A l though our own experience with donor
granulocytes has been small and disappointing, there is clear evidence of benefit
in the hands of others." One observation
seems clear: random donor granulocytes
have a poor record. One should obtain
relatives, preferably siblings, as donors. At
times the urgency of the clinical situation
may preclude an HL-A matching, at least
until after the first collection and administration. The two methods of collection are
by 1) differential centrifugation and 2) continuous flow filtration leukopheresis (CEEL).
The first method involves the use of a blood
cell separator, and 100% increase granulocyte yields from the donor can be procured by administering etiocholanolone 12
hours priorto donation. Further increases in
yields can be obtained by using hydroxyethyl stars (HES), a glucopyranone polymer
derived from waxy sorghum cornstarch.
This material, introduced into the separator,

The use of fresh frozen plasma and prothrombin complex concentrates, such as
Konyne, have no place in the management
of leukemic patients. The former might be
used to correct one or more clotting factor
deficiencies, should they occur not as a
result of disseminated intravascular coagulation, but this situation must be rare.
Prothrombin complex concentrates should
probably be used only to treat patients with
Christmas disease. This material probably
contains a thromboplastic contaminant,
and its use has produced intravascular coagulation and large vessel t h r o m b o s i s . I t
also is a common source of hepatitis virus.
The disseminated intravascular coagulation (DIC) syndrome occurs commonly as a
complication of progranulocytic leukemia.
Evidence for it, such as decreased fibrinogen and increased fibrin split products,
should be routinely sought in this disease.
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promotes rouleaux of red cells and thereby
delineates better the granulocyte layer. By
use of these techniques, 2.73 x I C granulocytes per litre of donor blood processed
was obtained by McCredie et a l . ' In contrast, Djerassi,'" using two nylon fiber filters
in parallel to collect granulocytes and then
eluting them off the filters in a continuous
flow system, processed 10-18 litres of blood
in three hours. The granulocyte yield is
much greater than by differential centrifugation, averaging 37.5 x 10' cells. These
granulocytes have been shown to retain
normal function, ie, ingestion of bacteria
and latex particles, and migration to sites of
infection. However, pyrogenic reactions are
increased in the recipient as compared to
separator prepared cells even in HL-A
matched donors. In favor of CFFL is the
relatively low cost, and the ease of re-using
the same donor, since only 30 cc of red
cells are sacrificed at each donation. As
methods are refined, we can reasonably
expect to have useful granulocyte transfusions as adjunctive support to the leukemic
patient in a few years.

nosis of the leukemia. At other times infection occurs duringthe course of early chemotherapeutic efforts at attaining remission.
As a rule of thumb, an absolute neutrophil
count below 500/cu mm, certainly below
200/cu mm, carries with it almost sure
promise of bacterial invasion of the host.
Furthermore, neutropenic patients may fail
to elicit the expected signs of local inflammation at infected sites, and may not necessarily have significant fever. On the other
hand, a leukemic patient who suddenly
shows a fever of 38.5°C ( l O r P ) , or more,
surely has an infection and should be treated as such with all urgency. Acute leukemia
per se may produce a low-grade fever, but
never as high as l O T R Drugs sometimes
produce this high fever and cause confusion
in the patient already receiving antibiotics
or antileukemic agents. Sites of trauma,
such as the mouth and anal region are
frequently the portal of entry for infecting
agents, as is the respiratory tract and skin.
Local lesions should be sought, since their
presence may suggest the most likely infecting organism(s). For example, £ coll, and P
aeruginosa are often cultured from perirectal and rectal abscesses; gram negative bacteria and fungi from pharyngitis; Klebsiella
sp organisms, and fungi from pneumonia; E
coli from urinary tract infections; and S
aureus from skin lesions.

Plasmapheresis
Although not strictly pertinent to the topic
of supportive management of the leukemic
patient, it is probably valid to mention the
proven value of plasmapheresis in myeloma
and lymphoma patients with extreme levels
of serum globulin. The occurrence of a
hemorrhagic state due to impairment of
platelet function or fibrinogen conversion
by excess globulin and/or manifestations of
the hyperviscosity syndrome both can be
satisfactorily controlled with this technique.

In 90% of cases sepsis was due to either P
aeruginosa, E coll, or K pneumonia in a
1968 study at M.D. Anderson Hospital"
(see table 1). Other institutions vary somewhat as to which are the most prevalent
organisms causing septicemia. The clinician should be familiar with the local current experience in this regard. It is noteworthy in a given patient that once an organism
produces clinical disease which responds to
treatment, a second episode of infection is
very likely to be due to this same organism.
LJnfortunately, there are too many exceptions to this rule to be useful in the overall
therapeutic plan. Acknowledging that it
may be difficult to recognize sepsis in this
group of patients, nonetheless, the pro-

II. Infection
It is a rare patient with acute leukemia
who does not become "infected" by bacterial or fungal organisms. Often infection
produces the initial awareness of illness
which leads to medical care and the diag-
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Table 1

gram is followed for eight days unless a
specific organism is recovered which would
dictate an appropriate change in the regimen. For example, recovery of an anaerobic Bactero/des resistant to p e n i c i l l i n
might warrant a change to clindamicin.'^ If
the organism is not recovered, and the
patient remains clinically septic, all antibiotics are discontinued around the eighth
day, and additional cultures obtained after
48 hours. However, many patients respond
promptly to this program. Others survive
long enough so that neutrophils repopulate
the circulation if marrow recovery occurs.
Frequently, all signs of sepsis disappear
when the polymorphs return. Relapses, occurring with subsequent vagaries of the
disease or with cyclic chemotherapy require repetition of the same prompt attack.

BACTERIAL ORGANISMS PRODUCING
SEPSIS IN LEUKEMIC PATIENTS
1) Pseudomonas aeruginosa

4(D%

2) Escherichia coli

30%

3) Klebsiella pneumoniae

20%

4) Staphylococcus aureus

3%

5) Proteus vulgaris

2%

6) Others

57o

Data is derived from unpublished observations
by GP Bodey, M.D., Houston, Texas, in 1968.
phylactic use of antibiotics is unwise. It has
been clearly shown that the longer such a
patient receives antibiotics, the greater his
chances of acquiring an infection due to
resistant organisms. Greene et al reported
superinfections in patients taking a threedrug antibiotic treatment, ie, 12%, 25%,
and 50% after 6, 12, and over-12 days
respectively.'^ On the other hand, delay in
starting treatment of septicemia until there
is cultural proof will result in a high percentage of failure.

Because of the frequency of monilial
stomatitis, pharyngitis, and esophagitis, particularly in neutropenic patients receiving
corticosteroids, mycostatin oral suspension
is prescribed prophylactically during the
periods of risk. This practice does not seem
to create any new problems and is effective
in controlling and/or eradicating oral candidiasis. Other important preventive measures i n c l u d e a v o i d a n c e of intravenous
catheters, changing intravenous needles every 48 hours, and changing intravenous
tubing daily. Also, one should avoid using
urinary catheters or any other invasive procedure not clearly of ultimate benefit to the
patient. Skin care is of unusual importance
in this clinical setting. Prompt attention to
even the most innocuous-appearing lesion,
t r i m m i n g finger and toe nails, regular
bathing, avoiding wetness and maceration
of skin, all must be included in the nursing
regimen. The bacterial burden to the patient
can be reduced to a significant degree by a
private room and by practicing a simple
form of reverse isolation. We require personnel attending the patient to use gown,
mask, and gloves. Potential sources of
pathogens such as respiratory equipment,
ice machines, bath tubs, etc., should be
monitored by periodic culturing.

With these considerations in mind, the
followingmodus operandi seems most logical in the management of the acute leukemic patient: At the first clinical clue that
sepsis is present, cultures of blood, sputum,
throat, and urine are taken, along with a
chest x-ray. A three-drug antibiotic regimen, consisting of gentamicin, carbenicillin
and cephalothln is given via a parenteral
route. There is evidence that carbenicillin is
more active in the presence of neutropenia
than the other agents. Furthermore, carbenicillin and gentamicin seem to be synergistic in Pseudomonas infections. Gent a m i c i n and c e p h a l o t h l n p r o b a b l y w o r k
synergistically in Klebsiella infections, and
a l l c o m m o n i n f e c t i n g b a c t e r i a are
"covered" by these three drugs. This pro-
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Table 2

acute leukemia, candidiasis has strikingly
increased. Pseudomycelial forms of Candlda in the urine suggest the presence of the
disseminated form of the disease while finding Cand/da in blood or marrow cultures, in
the absence of i n d w e l l i n g intravenous
catheters, v i r t u a l l y establishes the d i a g nosis. Despite its toxicity, amphotericin B
should be used in this latter circumstance.
5-Fluorocytosine, a new oral antifungal
agent, has been disappointing in disseminated candidiasis in the compromised host,
although synergism with amphotericin B
has been described.'"

NON-BACTERIAL INFECTIONS
SEEN IN LEUKEMIC PATIENTS
Candidiasis
Aspergillosis
Mucormycosis
Varicella-Zoster
Cytomegalovirus disease
Pneumocystis Carinii Pneumonia

The second most common fungus invader in the leukemic patient, also with increasing incidence is Aspergillus, rarely recognized ante-mortem and even less often
treated successfully. This species generally
attacks the respiratory tract. Chest roentgenograms show a variety of pulmonary
abnormalities in already severely ill patients. At autopsy, widespread involvement
of the gastro-intestinal tract, brain, liver and
kidney is often found. More aggressive diagnostic efforts, such as bronchial brushing,
closed needle aspiration, or even open lung
biopsy, may make it possible to recognize
invasive disease in time to render effective
antimycotic therapy with amphotericin B.

Toxoplasmosis
Viral hepatitis
Cryptococcal meningitis

Fungal and Protozoal
Infections
Table 2 is an incomplete list of nonbacterial causes of infection seen with increasing frequency in immunosuppressed patients. These include fungal, protozoal and
viral organisms.

Mucormycosis should be considered in
chronically ill, neutropenic, immunologically deprived individuals who demonstrate
in addition the triad of orbital cellulitis,
sinusitis, and diabetes mellitus (generally
poorly controlled). Diagnosis requires a biopsy of infected tissue from skin, palate, or
lung since o r d i n a r y fungus cultures are
rarely posftive.

Candidiasis in pharynx and urine generally represents superficial infection, but
substernal pain and dysphagia may indicate
invasive esophagitis. These symptoms in the
presence of other e v i d e n c e of o r o pharyngeal thrush should virtually establish
the diagnosis, although esophagograms,
esophagoscopy, and biopsy are decisive in
questionable cases. I n t h e i m m u n o s u p pressed neutropenic patient with acute leukemia, late stage chronic leukemia or lymphoma, Candida organisms, (ie, albicans,
troplcalis, and other species) are the most
common fungal offenders. Their presence
should be suspected if a patient fails to
recover satisfactorily from antibacterial
therapy or has a late febrile relapse. Since
the advent of aggressive chemotherapy in

Cryptococcosis and histoplasmosis are
rarely seen in acute leukemia, but continue
to occur in the late stages of chronic leukemia and lymphoma. Patients who seem to
be failing in a nondescript way, with or
without fever, and without obvious progression of their basic hematologic disease, may
have one of these latter two fungal diseases.
In addition, disseminated toxoplasmosis or
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Pneumocyst/'s carinii pneumonia are occasionally responsible for the same clinical
picture, although Pneumocyst/s is almost
always accompanied by dry cough, tachypnea, and objective signs in the chest.

Cancer Institute indicates about a 5 0 %
clinical recovery overall, and 80% in patients who received treatment for 7 days or
more.'

Cryptococcus neoformans meningitis,
when present, only yields a 50% positivity
on India ink preparations of the cerebrospinal fluid. One should always culture the
spinal fluid as well as the sputum and urine
in suspected cases. Complement fixation or
latex agglutination tests of the spinal fluid
are also helpful. Histoplasmosis, of all the
fungi, is most successfully cultured from
blood or bone marrow with positive results
in 50% of disseminated cases." Should the
signs of Addison's disease occur during the
course of chronic leukemia or lymphoma,
the most likely causes are histoplasmosis or
myleran toxicity. Disseminated or adrenal
tuberculosis has become less common in
recent years. Biopsy of oral ulcers may
disclose the presence of the typical-appearing fungus. The combination of amphot e r i c i n B and 5-Fluorocytosine is o c c a sionally successful against cryptococcosis
and histoplasmosis.

Viral Infections
Chronic lymphocytic leukemia and lymphoma patients are particularly prone to
some, but not all, viral disease. The predominant culprits are herpes viruses, inc l u d i n g varicella-zoster, simplex, and
cytomegalovirus. In addition, vaccinia and
measles produce more severe clinical disease in these patients. As a general rule it is
wise to avoid using any vaccine which
contains live and/or attenuated virus in
potentially immunosuppressed subjects.
Varicella-zoster either in its typical dermatome or disseminated distribution is easily r e c o g n i z e d . If deemed necessary, a
Tzank test can be performed to confirm the
etiology. This consists of finding, under light
microscopy, intranuclear inclusions in multinucleate giant cells from scrapings taken
from the base of vesicles, stained by the
Giemsa method. Both the local and disseminated (chicken pox) form of the disease
are more severe, the latter being life-threatening, as is the pneumonic form. ZIG (zoster immune globulin) is an effective passive
s u p p r e s s a n t o f v a r i c e l l a in e x p o s e d
children, but it must be given within 72
hours of exposure. Since zoster is thought to
be a reactivation of a dormant varicella
virus in adults and, clearly, prophylaxis is
not feasible, ZIG would appear to be useless in the latter. Furthermore, the large
dose (0.5 ml/kg) is impracticable. In adults
who develop severe herpes, the use of
adenine arabinoside (Ara-A) has recently
shown promise. Cytosine arabinoside (AraC) and idoxyuridine (lUDR) have not been
effective, although the latter (lUDR) is of
proven value in herpetic keratitis. Ara-A in
the recommended dosage, 10 mg/kg/day x
5 days in continuous intravenous drip, is
less toxic to marrow and immuno-suppressive than Ara-C and other antimetabolites.

Toxoplasma gondii disseminates in immunodepressed hosts, producing a serious
preterminal condition. Because of central
nervous system (CNS) involvement, mental
symptoms, cranial nerve palsies and motor
paresis occur. Although rising titres of Toxoplasma antibodies are diagnostic, it may
be quicker to obtain a biopsy of a lymph
node, where typical pathologic changes
can be recognized. Treatment c u r r e n t l y
g i v e n is t h e c o m b i n e d u s e o f
pyrimethamine and sulfadiazine for four
weeks.
To recover the organisms of Pneumocystis carinii, one must generally perform open lung biopsy although a few
reports of success with bronchial brushings
and tracheal aspirations are available.
Treatment for this protozoan organism in
established cases is pentamidine isethionate
for two weeks. Experience at the National
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Wfth regard to herpes simplex (hominis)
infection, suffice it to say that the local skin
or mucous membrane lesion may develop
an extensive area of cellulitis in compromised hosts. Occasionally, one of these
patients will develop an atypical indolent
encephalitis which mimics progressive multifocal leukoencephalopathy. Brain biopsy
is required to establish the etiology of the
CNS symptoms. A study to evaluate treatment with Ara-A is underway,"" but the
problem of securing a patient population
with proven herpes encephalitis is obvious.
lUDR has been found unacceptably toxic in
this condition.'^

The immunosuppressed patient, if i n fected with rubeola virus, may succumb to
a severe pneumonic process. This virus,
which can be recovered from normal individuals only up to 48 hours after disappearance of the rash, has been shown to
persist in leukemic patients' respiratory
tracts for long periods. Successful passive
i m m u n i z a t i o n w i t h c o m m e r c i a l gamma
globulin in a dose of 0.25 ml/kg can be
accomplished if given within 48 hours of
exposure, and modification of the severity if
given within five days of exposure.

Hepatitis B is an on-going problem in the
management of leukemia and lymphoma
patients, because of the usual high transfusion requirement. The incidence decreases
if only healthy, Australia antigen-negative
volunteers are used as a source of blood for
transfusion in contradistinction to commercial donors. Although gamma globulin intramuscularly can protect against hepatitis
A, it is not predictably effective against type
B exposures. Furthermore, it is impracticable to carry out long term prophylaxis with
this passive immunization method. Current
research is pointing the way toward inacfivation of the virus in the donor blood prior
to its administration. A 75% reduction in
the incidence of icteric hepatftis has been
described by incubation of donor blood
with gamma globulin.^" Also, active immunization wfth a vaccine consisting of a heatinactivated Australia antigen is under trial.
In treating the patient wfth viral hepatitis, it
is best to refrain from the use of corticosteriods early in the clinical course,
since this therapy has been shown to be
associated wfth an increased incidence of
chronic sequelae and the Australia antigen
carrier state.

The occurrence of clinical symptoms due
to cytomegalovirus does not seem to be
more prevalent in leukemia and lymphoma
patients. However, the manifestations are
so variable that the present status of this
entity is vague at best. A prospective study
at the National Cancer Institute tried to
clarify points regarding the significance of
virus excretion in throat or urine in relation
to cryptogenic fever, rash, or pneumonitis,
and also evaluate the presence of hemagglutinating antibody and complement-fixing antibody.'" Patients with severe pneumonitis, rash and fever, with demonstrated
virus in throat or urine, and a fourfold
antibody rise should probably receive antiviral agents, such as Ara-A or ILIDR.

Because of the likelihood of severe local
reaction or generalized d i s s e m i n a t i o n ,
smallpox vaccination should be avoided in
patients with chronic lymphocytic leukemia
or lymphoma. Nonetheless, despite this admonition, vaccinia gangrenosa, eczema
vaccinatum, or generalized vaccinia will
continue to occur among the unwary. VIG
(vaccinia immune globulin), in 0.6 ml/kg
intramuscular dosage, is sometimes successful in controlling these often fatal manifestations." Marboran, a thiosemicarbazone, has also been shown to be effective. The drug is taken orally in doses of 200
mg/kg/daily for four days.

III.

Metabolic Abnormalities

In acute leukemia, the most common
metabolic disturbances are shown in Table
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drugs may be responsible for significant
ionic shifts. For the present, it is well to
realize that, although hypokalemia may be
present before any treatment of the leukemia is begun, most often it appears sometime during the complex post-treatment
period. It makes a major contribution to the
patient's morbidity. The condition is generally slow to respond to potassium replacement, but obviously the attempt should
be made, if renal function is grossly satisfactory.

Table 3
METABOLIC DISORDERS ASSOCIATED
W ITH LEUKEMIA AND LYMPHOMA
1) Positive Na balance, fluid overload
2) Hyperkalemia and Hypokalemia
3) Hyperuricemia
4) Hypercalcemia

Hyperuricemia
3. The occurrence of hyponatremia and
h y p o c h l o r e m i a as a result of excessive
losses in the gastrointestinal efflux requires
appropriate replacement by parenteral fluids. However, conversely, one often sees
hypernatremia and/or vascular congestion
from excessive sodium intake, associated
with large doses of carbenicillin in conjunction with the need for blood products and
intravenous chemotherapy.

Hyperuricemia occurs frequently in patients with both chronic and acute leukemia
of all cell types. The serum uric acid level
fluctuates with disease activity and with the
state of renal function. Treatment with radiation or cytotoxic drugs, particularly in the
presence of a high tumor cell mass, can be
expected to produce an increase in the
serum level. It is also a burden on the renal
mechanism for excretion of urates, whether
the pretreatment serum uric acid level was
elevated or not. The development of acute
renal failure as a result of uric acid nephropathy is an acknowledged and dreaded
complication of this urate overload. Yet,
despite its documentation in the literature, it
must be quite rare, judged by the author's
e x p e r i e n c e . Nonetheless, it is accepted
practice to give allopurinol to the patient
wfth elevated serum uric acid or to the
patient wfth high tumor cell mass in whom
one anticipates a rapid cell kill. An inhibitor
of xanthine oxidase, allopurinol protects the
serum and kidneys from a large urate load.
But, it is still wise to alkalinize the urine and
push fluids in c o n j u n c t i o n w i t h radiotherapy and/or chemotherapy since there
is the possibility of producing xanthine calculi with these treatment modalities. Allopurinol is excreted by the kidney and the
dose should be reduced in the presence of
renal failure. The average dose of 300-600
mg/day is reduced to 200 mg for a

Hyperkalemia and Hypokalemia
Recently the findings of hyperkalemia^'
and hypokalemia^'' have been described
during the course of acute leukemia. The
hyperkalemic state has been explained, at
least theoretically, by the release of potassium from leukemic cells but, paradoxically, hypokalemia has also been found in
the presence of high total body potassium."
A renal tubular defect, possibly associated
with excess lysosyme excretion seen in
monocytic and myelomonocytic leukemia
may account for a high potassium excretion
rate and a consequent low serum level but
the explanation is almost certainly more
complex. The antibiotics gentamicin and
carbenicillin may induce urinary potassium
loss. By altering cell membranes, cytotoxic
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creatinine clearance of 10 ml/min. High
doses (600-800 mg) are given just prior to
major treatment thrusts. One should also be
aware that the interaction of allopurinol
wfth sorne chemotherapeutic agents, eg,
cyclophosphamide, results in greater marrow depression than with the latter alone.

ward correction of the hypercalcemia can
render a very gratifying improvement in the
patient's well-being as well as in other
biochemical abnormalities. On the other
hand, untreated prolonged hypercalcemia
leads to irreversible renal failure, metastatic
calcifications, cardiac arrhythmias, shock
and death. Therefore, we should consider
hypercalcemia (above 11.5 mg %) as a
medical emergency, requiring the following
corrective measures in decreasing order of
priority.

Obviously, the occurrence of renal shutdown, in a clinical setting which suggests
uric acid nephropathy, would be managed
by the measures usually employed, no matter what the underlying cause; ie, fluid
intake adjusted to maintain normal hydration (insensible losses plus urine output),
allopurinol in reduced dosage to adjust for
impaired output, and alkalinization. Hemodialysis would be preferable to peritoneal
dialysis, should uremia supervene.

1) Rehydrate with adequate fluid replacement to yield a daily urine output of 3 to 4
litres.
2) Administer furosemide (Lasix) following inftial rehydration. This agent is particularly effective in inducing calcium excretion, since it acts to block tubular reabsorption of sodium (and therefore, calcium
at the same site).

Hypercalcemia

3) Give high dose corticosteriods which
promptly lower the serum calcium in multiple myeloma patients, less predictably so in
other cancer patients. The mechanism of
action is thought to be through decreasing
bone absorption.

Acute and chronic leukemia are rarely, if
ever, accompanied by a pathologic degree
of hypercalcemia. On the other hand, the
condition occurs fairly commonly in uncontrolled myeloma (10%-20%), and occasionally in lymphomas or other malignancies in which bony involvement is a clinical
feature. Indeed, the presence of hypercalcemia may alert the clinician to an otherwise silent spread of disease to the bones.
The symptoms of hypercalcemia are nonspecific, but they are suggestive to the alert
physician: lethargy, depression, constipation, anorexia, and even nausea and vomiting. The patient is generally dehydrated and
shows obtunded or absent deep tendon
reflexes. Frequently, there is an associated
hyperuricemia with or wfthout variable degrees of azotemia. Measures directed to-

4) If the first three measures are ineffectual, one should use mithramycin in a single
intravenous injection of 25 ug/kg." This is
far below the anti-tumor dose and should
not significantly affect marrow function. It
also acts by inhibiting bone absorption, and
a favorable change in serum calcium is
generally observed within 24 to 48 hours.
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